Observational study of cancer drugs for breast and gynecologic cancers in routine care
Compares drug effects and side effects in breast and gynecologic cancer patients.
Plain-language title generated from the registry record
Registry title: Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers
Key facts
- Where
- Bologna, ItalySee the site
Where in Italy
- IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Trial code
- NCT06800612
- Record updated
- 30 January 2025
- Original description
retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and side effects compared with registry studies in the medical therapy of breast and gynecologic cancers.Read full original descriptionShow less
Observational Study Evaluating the Efficacy and Tolerability of Anticancer Drug Therapies Adopted for the Treatment of Gynecologic and Breast Cancers in Clinical Practice Compared with the Results of Registration Studies
retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and side effects compared with registry studies in the medical therapy of breast and gynecologic cancers.
Inclusion: Diagnosis of histologically confirmed breast cancer or gynecological cancer, either early stage or metastatic; Patients who have received treatment for breast cancer or gynecologic cancer since January 2010; Any patient currently living and actually contactable must sign an informed consent to the study and processing of personal data.
Exclusion: no exclusion criteria.